Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society.

doi:10.1136/thx.45.5.403

Cited by 91 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is mainly because of the absence of good controlled trials to compare different regimens. [ 8 25 – 27 ] Changes in guidelines regarding the number of drugs to be included in the regimen for the treatment of M/XDR-TB can be seen in the various American Thoracic Society (ATS) recommendations published in 1965,[ 27 ] 1966,[ 28 ] 1994[ 29 ] and 2003[ 30 ] Similar changes are also observed in British Thoracic Society (BTS) recommendations[ 31 32 ] and WHO recommendations from 1996,[ 33 ] 2003,[ 20 ] 1997[ 7 ] and 2008. [ 13 ] These changes are probably due to the availability of data from more case series.…”

Section: Introductionmentioning

confidence: 82%

Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies

Prasad

2012

Lung India

View full text Add to dashboard Cite

Multi-drug and extensively drug resistant tuberculosis (M/XDR-TB) has been an area of growing concern among clinicians, epidemiologists, and public health workers worldwide. Lack of controlled trials in M/XDR-TB patients hinders the optimal management of such patients, and guidelines that have been developed based largely on expert opinion are controversial. Lack of new effective drugs, improper regimens prescribed by poorly trained doctors and unreliable drug susceptibility testing add to the magnitude of the problem. M/XDR-TB is mostly a man made problem and its emergence can be checked by prompt diagnosis and effective use of first-line drugs in every new patient. DOTS-Plus proposed by World Health Organization (WHO) has highlighted the comprehensive management strategy to control multi-drug resistant tuberculosis (MDR-TB). Laboratory services must be strengthened for adequate and timely diagnosis of M/extensively drug resistant tuberculosis (XDR-TB) and programmatic management of M/XDR-TB must be scaled up as per target set by global plan to stop TB 2011-2015. In MDR-TB patients with localized disease, surgery, as an adjunct to chemotherapy, can improve outcomes and should be considered when there is poor response to appropriate chemotherapy. Proper use of second-line drugs must be ensured to cure existing MDR-TB, to reduce its transmission and to prevent emergence of XDR-TB.

show abstract

Section: Introductionmentioning

confidence: 82%

Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies

Prasad

2012

Lung India

View full text Add to dashboard Cite

show abstract

“…Finally, PZA is added to the treatment regimen at a dose of 250 mg/d, which is gradually increased to a range of 1‒1.5 g per day over 2‒3 days. 19 …”

Section: Discussionmentioning

confidence: 99%

Managing Hepatotoxicity Caused by Anti-tuberculosis Drugs: A Comparative Study of Approaches

Abbaspour,

Hasannezhad,

Khalili

et al. 2024

Arch Iran Med

View full text Add to dashboard Cite

Background: Tuberculosis (TB) is one of the oldest and most well-known diseases that has been associated with humans for many years and remains a global health challenge today. Timely diagnosis and proper treatment are crucial for controlling and preventing the spread of the disease. While anti-TB drugs offer many benefits, inadequate monitoring can lead to a range of side effects, including hepatotoxicity, which is a major concern and can cause treatment discontinuation. The aim of this study was to determine the approach to the hepatotoxicity of anti-TB drugs and to investigate potential relationships between demographic factors, underlying medical conditions, and successful retreatment outcomes for hepatotoxicity induced by anti-TB drugs. Methods: For this study, we reviewed the medical records of patients who experienced hepatotoxicity due to anti-TB treatment and were admitted to the infectious ward of Imam Khomeini Hospital between April 2015 and February 2019. The data were collected using a questionnaire. Results: The findings indicated that the female gender, weight loss at the beginning of hospitalization, hepatitis C virus, hepatitis B virus (HBV), heart disease, and high levels of aspartate aminotransferase (AST) and alanine transaminase (ALT) at the beginning of hepatotoxicity are risk factors for failure to the retreatment of hepatotoxicity. There were two different approaches to the anti-TB retreatment regimen. The first approach involved gradually starting the drugs in full dose, while the second approach encompassed starting the drugs in the minimum dose and then increasing to the maximum dose. The results demonstrated no significant difference between the two approaches to managing hepatotoxicity induced by anti-TB drugs. Conclusion: Drug-induced hepatotoxicity is a common occurrence that often results in treatment discontinuation. Understanding the prevalence of this complication and identifying appropriate methods of rechallenge treatment is crucial to reducing complications and mortality rates.

show abstract

“…It is currently recommended that extrapulmonary TB should be treated with triple therapy, i.e. isoniazid and rifampicin for six months plus pyrazinamide for the first two months 8 . A fourth drug, such as streptomycin or ethambutol, should be added initially if drug resistance is suspected, particularly in patients who may have imported the disease from a developing country.…”

Section: Discussionmentioning

confidence: 99%

“…isoniazid and rifampicin for six months plus pyrazinamide for the first two months. 8 A fourth drug, such as streptomycin or ethambutol, should be added initially if drug resistance is suspected, particularly in patients who may have imported the disease from a developing country. Major adverse reactions are not common but liver biochemistry should be assessed before treatment starts.…”

Section: Discussionmentioning

confidence: 99%

Splenic Tuberculosis: An Unusual Sonographic Presentation

Chandra

Gandhi

1999

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYTuberculosis (TB) of the spleen is rare, especially in the immunocompetent. Recently there has been an increase in the incidence of splenic TB, primarily attributable to the raging HIV epidemic. Almost all cases of splenic TB present as multiple hypoechoic foci (<2 cm) on ultrasonography. We present a case of a large solitary splenic tuberculoma in a middle‐aged, non‐immunosuppressed female, an employee at the local TB hospital. To the best of our knowledge, only two such cases have been described on ultrasound before. We suggest that, regardless of immune status, splenic TB should be considered as a diagnostic possibility when dealing with the solitary nodules of the spleen, especially when there is a history of exposure to or evidence of tuberculous foci elsewhere in the body.

show abstract

Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society.

Cited by 91 publications

References 22 publications

Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies

Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies

Managing Hepatotoxicity Caused by Anti-tuberculosis Drugs: A Comparative Study of Approaches

Splenic Tuberculosis: An Unusual Sonographic Presentation

Contact Info

Product

Resources

About